Evidence map›Paper›PMID 35741214›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Hepcidin as a Sensitive and Treatment-Responsive Acute-Phase Marker in Patients with Bacteremia: A Pilot Study.

Kreon Koukoulas, Vasiliki Lygoura, Philip Kartalidis, Nikolaos K Gatselis, Efthymia Petinaki, George N Dalekos, George Simos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kreon KoukoulasLaboratory of Biochemistry, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Vasiliki LygouraDepartment of Medicine & Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, 41100 Larissa, Greece.
Philip KartalidisDepartment of Medical Biopathology, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.
Nikolaos K GatselisDepartment of Medicine & Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, 41100 Larissa, Greece.
Efthymia PetinakiDepartment of Medical Biopathology, Faculty of Medicine, University of Thessaly, 41100 Larissa, Greece.
George N DalekosDepartment of Medicine & Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, 41100 Larissa, Greece.ORCID 0000-0001-7075-8464
George SimosLaboratory of Biochemistry, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0001-5453-3185
University of Thessaly · GRUniversity Hospital of Larissa · GR

Funding

Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE T1EDK-00204 BIOIRON
6 · The paper itself

Abstract

Hepcidin regulates iron metabolism by inhibiting intestinal iron absorption and iron release from iron stores. In addition to iron overload, inflammatory conditions also up-regulate hepcidin synthesis, which may serve as an antimicrobial defense by reducing iron availability to the invading microbes. The purpose of this study is to test this hypothesis in human patients by determining serum hepcidin concentration by enzyme linked immunosorbent assay (ELISA) in healthy blood donors (

Indexed as

acute phase markerbacteremiaCRPferritinhepcidin

Identifiers

PMID35741214
PMCPMC9221808
OpenAlexW4282020629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.